Oncoinvent ASA earnings date
Oncoinvent ASA (7BG) Q3 2026 Earnings Report
DE:7BG Q3 2026 EPS Results
- Actual EPS
- ―
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 8.42
DE:7BG Q3 2026 Revenue Results
- Actual Revenue
- ―
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/17/2026
- Time
- TBA
- Conference Call
- Tuesday, November 17, 2026
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, with strong Phase II recruitment, expanding clinical infrastructure, stable cash burn, a NOK 148.5 million financing, runway into the second half of 2027 and active preparation for Phase III. The principal challenges were the April delay for a more mature efficacy readout, the still-unknown efficacy results, unresolved elements of the Phase III design and the need for additional funding or partners to finance a full Phase III study.
Management expects Q4 recruitment to be “trending similarly,” with recruitment continuing “more or less at the same pace for the rest of the year,” and expects the safety readout “before Christmas” with “75 plus” patients, a maximum follow-up of 18 months and a median of “somewhere between 6 to 8 months”; the efficacy readout is planned for “March, April” and “coming in April,” with around 40 patients having 9 months follow-up versus 20 in December, while the company has extended its runway into the second half of 2027, is preparing for a Phase III trial that “may be able to start” as early as next year, and currently assumes about 500 to 600 patients, with “more than 500 patients” discussed, using peritoneal disease-free survival as an endpoint if possible, while PFS “will very likely be something that's accepted.”
- Strong Phase II Recruitment ProgressOncoinvent had recruited 71 patients by the end of Q3, representing about two-thirds of the total population including the ITT and safety sets. The company recruited 44 patients through Q3, more than twice the number recruited in the comparable period last year and almost double the full-year 2025 total.
- Q3 and Q4 Recruitment MomentumQ3 recruitment was broadly on par with Q2, making the two quarters the company's best recruitment quarters so far. Recruitment remained strong despite the summer period and two weeks of scheduled manufacturing-site maintenance, and Q4 was tracking at a similar pace with no recruitment concerns reported.
- Expanded Clinical Site NetworkThe active clinical network reached 11 recruiting sites after the addition of the Hospital of Saint-Luc in Brussels during Q3. Five sites have been added during 2026, bringing the network close to double its prior size. The company continues to evaluate additional sites, including for potential Phase III participation.
- Clinical and Scientific ProgressOncoinvent published a dosimetry paper in the Journal of Nuclear Medicine and presented three abstracts at ESMO and EANM during the quarter.
- Successful NOK 148.5 Million FundraiseThe company completed a private placement and retail offering in late September, raising gross proceeds of NOK 148.5 million.
- Extended Cash Runway and Solid Cash PositionThe financing extended the company's runway into the second half of 2027. Cash was NOK 200 million at the end of September, providing what management described as a comfortable margin to prepare for the Phase III program and the planned efficacy readout.
- Stable Cash Burn Despite Higher ActivityCash spent was approximately NOK 110 million by the end of Q3, with monthly cash burn in the low teens. Management stated that this represented no significant increase versus the baseline earlier in the year despite substantially higher patient-recruitment activity.
- Progress Against 2026 PrioritiesManagement stated that the company remained on track with its 2026 priorities, including Phase II recruitment, clinical-site expansion, protocol amendments, cash-burn discipline and preparation for Phase III.
- Protocol Amendments Supported RecruitmentSeveral protocol amendments cleared earlier in the year lowered the threshold for patient inclusion. Management identified this as a key driver of faster recruitment and broader patient inclusion.
- Phase III Preparation UnderwayThe company is preparing for a potential Phase III start as early as next year, subject to the interim analyses and regulatory discussions. Preparations include trial-design work, discussions with the FDA and EMA, early engagement with CROs and clinical sites, and readiness for IND and CTA submissions.
- Manufacturing Scale-Up and Redundancy PlansOncoinvent plans to scale up manufacturing and reduce manufacturing risk by establishing a second manufacturing location through a CDMO, most likely in the United States.
- Planned Phase II Safety and Efficacy ReadoutsThe company plans a safety readout before Christmas involving 75 or more patients, with patient follow-up ranging from recent enrollment to a maximum of about 18 months and a median expected to be approximately 6 to 8 months. The first interim efficacy readout is planned for April, when approximately 40 patients are expected to have at least 9 months of follow-up, compared with approximately 20 in December.
- More Mature April Efficacy DatasetManagement stated that moving the efficacy readout to April would approximately double the number of relevant patients with at least 9 months of follow-up. In the control-group illustration, the number of relevant patients increases from approximately 7 in December to 13 in April, making the dataset more mature and increasing the probability of a meaningful interim analysis.
- Encouraging Prior Clinical ResultsManagement stated that two trials reported last year in cancers that metastasize to the peritoneum showed encouraging signs of efficacy and a great safety profile. These results supported the launch of the randomized Phase II ovarian-cancer trial.
- Defined Randomized Phase II DesignThe ongoing Phase II trial is planned to include slightly more than 100 patients randomized 2:1 to standard of care versus standard of care plus Radspherin. Patients are followed with imaging every three months for 24 months, with progression-free survival as the primary endpoint.
- Potential for Long-Term Survival Follow-UpAlthough the ovarian study's protocol follow-up is 24 months, the company can follow patients for survival for up to five years. Management said it intends to examine updated survival data in due course.
- Experienced Chief Medical Officer AppointedDr. Zuzana Jirakova Trnkova joined as Chief Medical Officer. She brings more than 20 years of experience across strategic, medical, operational and regulatory development roles, including Phase III and alpha-emitter experience.
- Large Unmet Need in Ovarian CancerManagement highlighted that up to 8 in 10 women with advanced ovarian cancer relapse after surgery despite no visible disease, with peritoneal micrometastases identified as a major cause of relapse. Ovarian cancer remains one of the deadliest gynecological cancers, and survival remains modest despite advances in treatment.
- Radspherin's Localized Treatment ApproachRadspherin is administered after surgery as a radioactive fluid into the abdominal cavity, where it remains active for a couple of weeks and is intended to eradicate micrometastases, single cancer cells and small nodules that may remain after surgery.
- Business Development and Partnering ActivityThe company continues business-development efforts and plans to engage with potential strategic or pharmaceutical partners. Management also scheduled participation in BIO-Europe, Jefferies Week, DNB's healthcare conference, the targeted radiopharmaceutical conference and J.P. Morgan's BIO Showcase and BIO Partnering events.
DE:7BG Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 17, 2026 | 2026 (Q3) | ―- | -8.42 | ― | |
| Aug 27, 2026 | 2026 (Q2) | ―-1.44 | -8.42 | 82.88% (+6.98) | |
| May 27, 2026 | 2026 (Q1) | ―- | ― | ― | |
| Feb 26, 2026 | 2025 (Q4) | ―-6.47 | -6.62 | 2.36% (+0.16) | |
| Nov 19, 2025 | 2025 (Q3) | ―- | -0.06 | ― | |
| Aug 27, 2025 | 2025 (Q2) | ―-8.42 | -8.45 | 0.35% (+0.03) | |
| May 21, 2025 | 2025 (Q1) | ―- | -0.09 | ― | |
| Feb 26, 2025 | 2024 (Q4) | -6.62-6.62 | -12.15 | 45.50% (+5.53) | |
| Nov 13, 2024 | 2024 (Q3) | -8.14-3.83 | -6.08 | 37.00% (+2.25) | |
| Aug 21, 2024 | 2024 (Q2) | -7.60-8.45 | -91.15 | 90.73% (+82.70) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

